PMID- 31115672 OWN - NLM STAT- MEDLINE DCOM- 20190627 LR - 20200225 IS - 1432-1335 (Electronic) IS - 0171-5216 (Linking) VI - 145 IP - 7 DP - 2019 Jul TI - Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma. PG - 1761-1772 LID - 10.1007/s00432-019-02936-w [doi] AB - PURPOSE: This study investigated the characteristics of tumor-associated immune cells (TAICs) in laryngeal squamous cell carcinoma (LSCC) and their correlation with clinicopathological variables. METHODS: The immune cell infiltrates of 71 specimens of stages I-IV LSCC were examined. The density of TAICs expressing CD3, CD4, CD8, CD68, and CD163 was assessed using immunohistochemical staining and image analysis in peritumoral and intratumoral regions. RESULTS: Higher densities of CD3+ and CD8+ cell and lower densities of CD68+ and CD163+ cell infiltrations were found in early tumor stages than in late tumor stages. A higher percentage of patients with strong CD3+ and CD8+ immune cell infiltration and weak CD68+ cell infiltration in both tumor regions presented with T1 stage tumors compared with T4 stage tumors. Further, strong CD68+ cells infiltration in both regions was observed in a greater number of patients who had a relapse, while a weak CD3+ cells infiltration in both regions was found in a greater number of patients with nodal lymphatic metastasis. The univariate analysis showed that a high density of peritumoral CD3+ and CD8+ immune cells in both regions was significantly associated with a favorable overall survival (OS) (P = 0.004; P = 0.006; P = 0.042). In contrast, a high density of intratumoral CD68+ cells and peritumoral CD163+ cells was significantly associated with poor OS durations (P = 0.026; P = 0.030). The multivariate analysis demonstrated that a high density of peritumoral CD163+ cells correlated with poor OS after adjusting for tumor stage, recurrence, and nodal lymphatic metastasis (P = 0.034). This study found different patterns of TAIC infiltration in LSCC. The density and location of TAICs infiltration correlated with the clinicopathological characteristics of LSCC. CONCLUSION: A combined analysis of the density of TAICs and their location may help predict patient survival and response to checkpoint inhibitors. FAU - Zhou, Liyuan AU - Zhou L AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Li, Yujun AU - Li Y AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Gao, Wei AU - Gao W AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Huangfu, Hui AU - Huangfu H AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Wen, Shuxin AU - Wen S AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Zhang, Chunming AU - Zhang C AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Zhao, Qinli AU - Zhao Q AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Dong, Zhen AU - Dong Z AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. FAU - Qu, Chongxiao AU - Qu C AD - Department of Pathology, Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, Shanxi, China. FAU - Li, Guodong AU - Li G AD - Department of Otolaryngology, Head and Neck Surgery, Shanxi Provincial People's Hospital, Shanxi Medical University, Taiyuan, Shanxi, China. FAU - Wu, Lina AU - Wu L AD - Department of Pathology, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. FAU - Wang, Binquan AU - Wang B AUID- ORCID: 0000-0001-6810-2968 AD - Department of Otolaryngology, Head and Neck Surgery, The First Hospital of Shanxi Medical University, 85 Jiefang South Road, Taiyuan, Shanxi, China. binquan_wang@hotmail.com. AD - Shanxi Key Laboratory of Otolaryngology Head and Neck Cancer, Taiyuan, Shanxi, China. binquan_wang@hotmail.com. LA - eng GR - 81872210/Major Research Plan/ PT - Journal Article DEP - 20190521 PL - Germany TA - J Cancer Res Clin Oncol JT - Journal of cancer research and clinical oncology JID - 7902060 RN - 0 (Antigens, CD) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Antigens, CD/immunology MH - Female MH - Humans MH - Immunohistochemistry MH - Laryngeal Neoplasms/*immunology/pathology MH - Lymphocytes, Tumor-Infiltrating/immunology/pathology MH - Male MH - Middle Aged MH - Neoplasm Staging MH - Retrospective Studies MH - Squamous Cell Carcinoma of Head and Neck/*immunology/pathology OTO - NOTNLM OT - Immunohistochemistry OT - Laryngeal squamous cell carcinoma (LSCC) OT - Tumor-associated immune cells (TAICs) EDAT- 2019/05/23 06:00 MHDA- 2019/06/30 06:00 CRDT- 2019/05/23 06:00 PHST- 2019/02/24 00:00 [received] PHST- 2019/05/13 00:00 [accepted] PHST- 2019/05/23 06:00 [pubmed] PHST- 2019/06/30 06:00 [medline] PHST- 2019/05/23 06:00 [entrez] AID - 10.1007/s00432-019-02936-w [pii] AID - 10.1007/s00432-019-02936-w [doi] PST - ppublish SO - J Cancer Res Clin Oncol. 2019 Jul;145(7):1761-1772. doi: 10.1007/s00432-019-02936-w. Epub 2019 May 21.